RxSight outlines 2028 earliest next-gen LAL timing as it plans to resume 2027 guidance

• CEO Aziz Mottiwala said his completed initial assessment set three priorities: "strengthen the U.S. LAL business, advance our next-generation adjustable lens pipeline and execute on the significant opportunity represented by our collaboration with Alcon," adding, "we

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.